We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HOLX Stock Set to Gain From New Study Data on Genius AI Detection 2.0
Read MoreHide Full Article
On Sunday, Hologic (HOLX - Free Report) presented new research evaluating the performance of its Genius AI Detection 2.0 software across diverse patient populations at the 110th Scientific Assembly and Annual Meeting of the Radiological Society of North America (“RSNA”). The research, titled “Performance of a Digital Breast Tomosynthesis AI Detection Algorithm in Common U.S. Racial/Ethnic Groups,” revealed that the measured performance of the algorithm was similar across all evaluated cohorts.
Hologic is also introducing its next-generation Genius AI Detection PRO solution for use in the United States, extending its leadership in breast imaging AI.
HOLX Stock’s Likely Trend Following the News
After the announcement on Dec. 1, HOLX shares dipped 0.6%, finishing at $79.00. Meanwhile, the Breast Health segment is driving growth through increased breast imaging service revenues, and contributions from the gantry business and interventional products. The company’s upcoming innovations are likely to see expanded AI applications for improved performance and efficiency. We expect the recent development to boost market sentiment toward HOLX stock.
Hologic currently has a market capitalization of $18.04 billion. The company’s earnings yield of 5.42% compares favorably with the industry’s yield of -5.62%. It delivered an earnings beat of 3.1%, on average, in the trailing four quarters.
Importance of Hologic’s Research Findings
AI is becoming an essential tool in breast cancer, aiding in diagnosis and predicting a patient’s risk level and breast density. The creation of AI algorithms starts with the collection of large, high-quality databases of patient information and images, which are used to develop, train and test the algorithms. By including a diverse range of racial and ethnic groups from the U.S. population in the databases, the developed algorithms minimize inherent biases that create disparities for specific patient groups. Hologic’s new study assessed more than 7,500 digital breast tomosynthesis (DBT) cases from women who identified as Asian, Black, Hispanic or white.
Significant racial disparities in breast cancer screening and treatment exist, with studies indicating that Black women in the United States have a 40% higher death rate from breast cancer than white women. The company says that it strives to provide clinicians with effective, equitable solutions to advance the detection of breast cancer globally, ensuring that its technology performs effectively for all patients regardless of race, ethnicity or background.
Image Source: Zacks Investment Research
Meanwhile, the company’s latest Genius AI Detection PRO solution expands on the Genius AI Detection 2.0 solution by providing even greater accuracy and efficiency, giving radiologists more confidence and helping reduce false positives.
Other Updates From Hologic
Last month, Hologic entered into a $350 million agreement to acquire Gynesonics, Inc., a company specializing in minimally invasive solutions for women’s health. The acquisition will bring Gynesonics’ Sonata System, a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding.
Industry Prospects Favoring Hologic
Per a research report, global AI in the Breast Imaging market was valued at $363.83 million in 2023 and is expected to expand at a compound annual rate of 28.9% by 2031. AI’s popularity in this industry has increased due to the creation of complex AI algorithms that can analyze huge amounts of imaging data.
HOLX Stock Price Performance
In the past six months, shares of Hologic have risen 5.9% compared with the industry’s 0.9% growth.
Penumbra shares have risen 7.8% in the past year. Estimates for the company’s 2024 earnings per share have jumped 8.1% to $2.79 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.
Estimates for Haemonetics’ fiscal 2025 earnings per share have jumped 0.4% to $4.59 in the past 30 days. Shares of the company have rallied 8.9% in the past year compared with the industry’s growth of 21.2%. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.
Estimates for Globus Medical’s 2024 earnings per share have increased 3.9% to $2.95 in the past 30 days. Shares of the company have surged 90.3% in the past year compared with the industry’s 15.1% rise. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%. In the last reported quarter, it delivered an earnings surprise of 27.69%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
HOLX Stock Set to Gain From New Study Data on Genius AI Detection 2.0
On Sunday, Hologic (HOLX - Free Report) presented new research evaluating the performance of its Genius AI Detection 2.0 software across diverse patient populations at the 110th Scientific Assembly and Annual Meeting of the Radiological Society of North America (“RSNA”). The research, titled “Performance of a Digital Breast Tomosynthesis AI Detection Algorithm in Common U.S. Racial/Ethnic Groups,” revealed that the measured performance of the algorithm was similar across all evaluated cohorts.
Hologic is also introducing its next-generation Genius AI Detection PRO solution for use in the United States, extending its leadership in breast imaging AI.
HOLX Stock’s Likely Trend Following the News
After the announcement on Dec. 1, HOLX shares dipped 0.6%, finishing at $79.00. Meanwhile, the Breast Health segment is driving growth through increased breast imaging service revenues, and contributions from the gantry business and interventional products. The company’s upcoming innovations are likely to see expanded AI applications for improved performance and efficiency. We expect the recent development to boost market sentiment toward HOLX stock.
Hologic currently has a market capitalization of $18.04 billion. The company’s earnings yield of 5.42% compares favorably with the industry’s yield of -5.62%. It delivered an earnings beat of 3.1%, on average, in the trailing four quarters.
Importance of Hologic’s Research Findings
AI is becoming an essential tool in breast cancer, aiding in diagnosis and predicting a patient’s risk level and breast density. The creation of AI algorithms starts with the collection of large, high-quality databases of patient information and images, which are used to develop, train and test the algorithms. By including a diverse range of racial and ethnic groups from the U.S. population in the databases, the developed algorithms minimize inherent biases that create disparities for specific patient groups. Hologic’s new study assessed more than 7,500 digital breast tomosynthesis (DBT) cases from women who identified as Asian, Black, Hispanic or white.
Significant racial disparities in breast cancer screening and treatment exist, with studies indicating that Black women in the United States have a 40% higher death rate from breast cancer than white women. The company says that it strives to provide clinicians with effective, equitable solutions to advance the detection of breast cancer globally, ensuring that its technology performs effectively for all patients regardless of race, ethnicity or background.
Image Source: Zacks Investment Research
Meanwhile, the company’s latest Genius AI Detection PRO solution expands on the Genius AI Detection 2.0 solution by providing even greater accuracy and efficiency, giving radiologists more confidence and helping reduce false positives.
Other Updates From Hologic
Last month, Hologic entered into a $350 million agreement to acquire Gynesonics, Inc., a company specializing in minimally invasive solutions for women’s health. The acquisition will bring Gynesonics’ Sonata System, a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding.
Industry Prospects Favoring Hologic
Per a research report, global AI in the Breast Imaging market was valued at $363.83 million in 2023 and is expected to expand at a compound annual rate of 28.9% by 2031. AI’s popularity in this industry has increased due to the creation of complex AI algorithms that can analyze huge amounts of imaging data.
HOLX Stock Price Performance
In the past six months, shares of Hologic have risen 5.9% compared with the industry’s 0.9% growth.
HOLX’s Zacks Rank & Key Picks
Hologic currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Penumbra (PEN - Free Report) , Haemonetics (HAE - Free Report) and Globus Medical (GMED - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Penumbra shares have risen 7.8% in the past year. Estimates for the company’s 2024 earnings per share have jumped 8.1% to $2.79 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.
Estimates for Haemonetics’ fiscal 2025 earnings per share have jumped 0.4% to $4.59 in the past 30 days. Shares of the company have rallied 8.9% in the past year compared with the industry’s growth of 21.2%. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.
Estimates for Globus Medical’s 2024 earnings per share have increased 3.9% to $2.95 in the past 30 days. Shares of the company have surged 90.3% in the past year compared with the industry’s 15.1% rise. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%. In the last reported quarter, it delivered an earnings surprise of 27.69%.